Ramin Sayar Buys Shares of Phreesia, Inc. (PHR)
Ramin Sayar purchased 19,290 shares of Phreesia for $184,991 on June 24, 2026.
Key Points
- Ramin Sayar bought 19,290 shares of Phreesia, Inc. at $9.59 each, totaling $184,991 on June 24, 2026.
- Phreesia, Inc. traded at $9.13 on Saturday with a market cap of $622.4 million and a P/E ratio of 62.9.
- Analysts have set price targets between $9 and $20, with a consensus rating of 'buy'.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 24, 2026, Ramin Sayar made a significant move by purchasing 19,290 shares of Phreesia, Inc. (NYSE: PHR) at an average price of $9.59 per share. This transaction, totaling $184,991, was not part of a pre-arranged trading plan.
Insider Buying and Selling at Phreesia, Inc.
Several insiders at Phreesia, Inc. made notable transactions recently. On June 24, besides Ramin Sayar, other insiders such as Lainie Goldstein, Mark Douglas Smith, and Gillian Munson also acquired 19,290 shares each at the same price. These transactions were not planned trades. Additionally, Lisa Egbuonu-Davis sold 2,546 shares on June 25 under a planned transaction.
Phreesia, Inc. Stock Down 17.1%
Shares of Phreesia, Inc. traded near $9.13 on Saturday. The company boasts a market capitalization of approximately $622.4 million. With a P/E ratio of 62.9 and a forward P/E of 6.3, the stock reflects investor expectations for future growth. Phreesia's beta stands at 0.884, indicating its volatility relative to the market. Over the past year, the stock has seen a low of $7.77 and a high of $32.76. The company's 50-day moving average is $9.38, while the 200-day moving average is $15.21.
$PHR stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
Analysts have been active in setting new price targets for Phreesia. On May 29, Truist Securities maintained a 'hold' rating with a $12 target. Citigroup also maintained a 'hold' rating on May 28, while Canaccord Genuity and DA Davidson maintained their 'buy' ratings with targets of $16 and $14, respectively. Notably, Wells Fargo downgraded the stock to 'hold' on May 20 with a $9 target. Overall, the consensus recommendation is a 'buy', with a mean price target of $13.94.
About Phreesia, Inc.
Phreesia, Inc. is a healthcare technology company based in Wilmington, Delaware. Founded in 2005, it offers a SaaS-based platform providing various solutions for healthcare organizations in the U.S. and Canada. These include appointment optimization, payment solutions, and patient engagement tools. The company serves a diverse range of healthcare providers and organizations, aiming to improve operational efficiency and patient experience.
Bottom Line
Ramin Sayar's purchase of Phreesia shares underscores confidence in the company's growth potential. Investors often track insider transactions for insights into company prospects. While this filing provides a snapshot of insider activity, it's important to remember such trades are reported after they occur.
Get Phreesia, Inc. alerts
New 13F filings, insider trades, and analyst moves on $PHR, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.